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Abstract  
Background: Inspite of 1000s of novel tumor markers in past 2 decades there is not even a single 
tumor marker which is proved to have diagnostic or prognostic value in oral squamous cell carcinoma 
(OSCC).  The purpose of this review is to examine the current status of the emerging novel tumor 
markers. Methods:  This search strategy was in accordance with the Cochrane guidelines for systemic 
review. Articles were selected using Pubmed search. The article search included only those published 
in the English literature. Results: Total of 12 tumor markers were analyzed. None of the tumor markers 
analyzed has all the qualities for a tumor marker like good sensitivity, specificity for diagnosis or 
assessing the prognosis Conclusions: Thus far, studies, although inconclusive, have found that the 
likelihood of identifying a biomarker with such sensitivity and specificity may be slim, at least for the 
immediate future.  
Key words: oral squamous cell carcinoma, novel tumor markers  
 
1. Introduction  
A tumor marker is a substance present in a tumor, or produced by the tumor and host, that can be used 
for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, 
cells, and/or tissues. Most commonly, a tumor marker is thought of as a biologic measurement that 
represents the disease quantitatively or in activity, which goes up when the disease progresses or 
relapses, and goes down when the disease is in to remission. Of vital importance for this biomarker, is 
that (the kinetics of) this substance is more easily measured, more quickly observed, and demonstrates 
enhanced sensitivity or specificity over established clinical decision tools. 
Although there is a large quantity of literature on prognostic and predictive factors, there is still a lack 
of validated molecular markers for measuring biological activity which is needed to help oncologist’s 
decision making to include patients for targeted pathways.  
The search for a perfect marker which satisfies all the criteria of an ideal marker has now lead to the 
discovery of  gene and gene products as tumor markers  which  appear in the normal and abnormal 
tumor tissue,  involved in the tumor growth, angiogenesis, cell signaling, proliferation and tumor 
invasion.   
Hence we systematically reviewed the expression of the new emerging tumor markers in oral 
squamous cell carcinoma published in the last 5 years which has a promising value in the near horizon. 
 
2. Methods  
2.1 Search strategy for identification of the studies: 
This search strategy was in accordance with the Cochrane guidelines for systemic review. Articles were 
selected using PubMed. The search strategy used terms for 3 categories – Oral squamous cell 
carcinoma, novel tumor markers and prognostic marker. We conducted the literature review of the 
studies examining the expression of the novel tumor markers in OSCC. Due to large number of tumor 
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markers in OSCC, we limited our search period between 2006-2011. The article search included only 
those published in the English literature.  
 
2.2 Selection Criteria 
The title of article and abstracts were reviewed. Articles which considered novel tumor markers in oral 
squamous cell carcinoma published from the year 2006-2011 were selected. Only articles which had a  
minimum of  45 cases were included for the review. Only immunohistochemical studies were included. 
Tumor markers analyzed using other diagnostic methods were excluded. Biomarkers in Head and neck 
squamous cell carcinoma were excluded. 
 
2.3 Data extraction and analysis: 
Once the final conclusion was attained regarding the articles to be reviewed, data extracted from each 
article was tabulated (Table 1, 2) and was later cross checked. 
 
3. Results  
3.1 Sensitivity : 
Among the tumor markers analysed only Septin has got 91% expression all the other tumor markers 
has got < 75% expression only, so the sensitivity of the tumor markers analyzed are not very good. Out 
of the 12 markers analyzed 3 of them TROP2, Tapasin and MUC4 do not have a statistically significant 
expression. 
 
3.2 Specificity : 
All the tumor markers are already evaluated in other tumors and tried for the first time in OSCC based 
on their function in the tumor growth and progression, so none of the tumor marker is specific for 
OSCC.  
 
3.3 Clinico pathological correlation: 
Till date prognosis in a OSCC is determined by clinical staging (tumor size, metastasis and Lymph 
node involvement) histopathological grading (well, moderate and poor differentiation). There is 
extensive search to find a prognostic marker independent of both.   
TROP2 and STAT1 do not have significant correlation with the clinical staging and histopathological 
grading.   
Periostin, mGluR5, Stathmin, MUC4 and Cyr61 has good clinical correlation but there is no 
statistically significant histopathological correlation. SENP5, Septin1 has significant histological 
correlation but there is no clinical correlation.  
Stromal Versican expression and Insulin like mRNA binding protein 3(IMP3) has got good clinical and 
histopathological correlation. 
 
3.4 Prognosis: 
Increased expression of TROP2, Stromal Versican, MUC4, IMP3, Stathmin, Periostin, mGluR5, Cyr61 
were associated with poor prognosis whereas decreased expression of Tapasin was associated with 
statistically significant poor prognosis and increased expression of STAT1 was associated with good 
prognosis.  
Septin1, SENP5 expressions were not associated with statistically significant survival outcomes 
Therapeutic target – TROP2, mGluR5, Stathmin, IMP3, Tapasin, Cyr61 are potential therapeutic 
targets.   
 
4. Discussion  
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To date various proteins related to diagnosis and prognosis have been introduced as tumor markers, 
including cytokeratin, tumor suppressor P53, cell adhesion molecules CD44, apoptosis inhibitor bcl2 
and cell proliferation markers Ki-67 and PCNA. The ability of these candidate markers to predict the 
presence of OSCC in patients is limited. So there is continuous and desperate search for an ideal tumor 
marker. We analyzed the emerging tumor markers. We systematically reviewed the tumor markers 
appeared in indexed journals in past 5 years. 
TROP2:  
The human trophoblast cell-surface antigen TROP2 (also termed GA733-1, M1S1, EGP-1) is encoded 
by the TACSTD2 gene, which has been mapped to the human chromosome 1p32 (Calabrese, 2001). 
TROP2, originally identified on human trophoblast and choriocarcinoma cell lines, was subsequently 
shown to be highly expressed by the majority of human carcinomas. Prior to OSCC TROP2 over 
expression was found in colorectal and esophageal cancer as well as pancreatic cancer.  Cases with 
overexpression of TROP2 in pancreatic cancer had poor prognosis.  Dominic Fong et al. (2008), 
studied TROP2 expression in OSCC and over expression was not found to be statistically significant 
and there is no significant correlation between the TROP2 expression and clinical and histopathological 
correlation. But TROP2 expression was found to have independent correlation to overall survival. So 
TROP2 is an independent prognostic marker. 
Periostin:  
Periostin is originally identified from osteoblasts and functions as a cell adhesion molecule for 
preosteoblast and to participate in osteoblast recruitment, attachment and spreading. Previous studies 
showed that the expression of Periostin is upregulated in various types of cancer, including head and 
neck (Gonzalez, 2003). Studies by Bao et al and Shao et al demonstrated that periostin promotes 
metastasis and angiogenesis in breast and colon cancers. Similar to the findings in the previous studies 
BSMS Siriwardene et al. (2006), study on periostin in OSCC also had a significant correlation with 
tumor metastasis. Because of its relation to metastasis its overexpression obviously associated with 
poor prognosis. So it could be a useful predictor for metastasis and poor prognosis. It is useful only as a 
predictive marker and has no role as a therapeutic target. 
SENP5:  
SUMOylation is one of the most important posttranslational modifications. The small ubiquitin-like 
modifiers (SUMOs) are ubiquitin-like proteins and as with ubiquitin, these modifiers are conjugated by 
a serial of enzymes to cellular regulators. Consequently, the localization, activity and stability of the 
substrates are changed (Gill, 2005). The SUMOylation can be reversed by SUMO-specific proteases 
(SENPs). Xiaojun Ding et al. (2008), studied the expression of SENP5 and found that there was no 
correlation to tumor size, lymph node metastasis or tumor staging but there was a significant 
correlation to histopathology. SENP5 is also not associated with statistically significant survival 
outcome. There is no role as a therapeutic target. Out of the tumor markers analyzed SENP5 is done in 
a very small sample size (48 cases), so to get a statistically significant results it needs to be repeated in 
a larger sample size.  
mGluR5 (Metabotropic glutamate receptor): 
The multifunctional G protein coupled metabotropic glutamate receptor (mGluRs) family comprises of 
8 subtypes. Glutamate was originally identified as excitatory neurotransmitter. Eventhough it is 
predominantly present in the neuronal cells, its signaling has been implicated in the growth and 
migration of various non neuronal cancers (Cavaelheiro, 2001). Some of these proteins play an 
important role in the tumor progression. mGluR 5 expression was studied only in lung adenocarcinoma 
and found to have overexpression.   So-yeon park et al. (2007), were the first to study mGluR5 in a 
squmous cell carcinoma, found have significant correlation to tumor size and staging but no correlation 
to histopathology. The study doesn’t show this as a therapeutic target. 
Septin1:  
Septin1's role in the regulation of cytokinesis is related to its phosphorylation by Aurora-B (Meiyan). 
Aurora-B is ‘chromosomal passenger’ protein that localizes to centromeres from prophase to 
metaphase, to the midzone of the mitotic spindle in anaphase, and to the midbody in telophase .Aurora-
B plays a crucial role in chromosome segregation and cytokinesis. Yoshikuni kato et al. (2007), studied 
that there is no significant correlation between Septin1 over expression and clinicopathologic features 
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with the exception of tumor differentiation in OSCC. Septin1 overexpression is not a prognostic 
marker. No role as a therapeutic target. 
Stathmin: 
Stathmin gene plays an important role in mitosis and other cellular processes which attracted many 
investigators to evaluate its role in cancer growth and progression (Rubin, 2004), subsequently found 
that high level of expression was found in Leukemia, lymphoma, prostatic carcinoma, ovarian 
carcinoma, breast carcinoma and adenoid cystic carcinoma. Y Kouzu et al. (2006), examined stathmin 
expression in OSCC and found there was significant correlation to clinical staging. Moreover the state 
of expression differed significantly between Stage I/II and Stage III/IV suggesting its role in tumor 
progression and aggressiveness. 
IMP3 ( Insulin like growth factor II m RNA binding protein 3): 
Insulin-like growth factor II mRNA-binding protein (IMP) family is associated with RNA trafficking 
and stability, and with cell growth and migration during the early stages of mouse and human 
embryogenesis (Meuller-Pillasch, 1999).  IMP3 is regarded as an important biomarker for various 
cancers, such as pancreatic cancer, lung cancer, renal cell carcinoma, and hepatocellular carcinoma. 
IMP3 is also an early biomarker for serous endometrial cancer and cervical adenocarcinoma in situ. 
IMP3 also regulates tumor cell proliferation, migration, and metastasis. Shengjin Li et al. (2009), 
IMP3-positive expression was correlated with several clinicopathologic factors, including high 
histopathologic grade, presence of lymph node metastasis, advanced tumor, and clinical stages.  IMP3 
expression in OSCC was associated with poor patient prognosis. 
Tapasin:  
Tapasin is a chaperone which is an important component of MHC class I pathway associated with 
antigen processing. The absence of Tapasin surface antigens has been reported in number of cancers 
and may represent a mechanism of tumor escape from control of immune system such as head and neck 
cancer (Ferris, 2005) ovarian cancer (Han, 2008).  Downregulation of Tapasin has been associated with 
failure of CTL (cytotoxic T lymphocytes) recognition  in squmous cell carcinoma of the head  and neck 
and is associated with significant decrease in overall survival probably because of the role of Tapasin 
in promoting the peptide binding in MHC I heterodimer and increasing the.peptide transport rate. In 
study by Qian jiang et al. (2010), Lack of Tapasin expression was observed in 43% (30 0f 67) cases 
which indicates poor sensitivity, but the lack of expression was associated with poor differentiation and 
poor prognosis (Negative Predictive Value).  Similar to the findings in other carcinomas. Qian jiang et 
al. (2010), reported lack tapasin expression is associated with overall poor survival in OSCC also. 
 
Stromal Versican:  
Versican, a member of the aggrecan gene family, is a large chondroitin sulphate proteoglycan plays a 
role in ECM assembly, anti-adhesion, cell proliferation, migration and extracellular matrix remodeling 
(Wight, 2002).  In oropharyngeal and hypopharyngeal tumours stronger versican expression was 
associated with lower stage In more advanced stages of both epithelial ovarian cancerand lung 
adenocarcinoma, stromal versican is more abundantly expressed. Owing to small number of published 
reports so far the association between stromal versican expression and clinicopathological tumour 
characteristics remain unclear. Mutti Pukkila et al. (2006) studied Stromal Versican expression in 
OSCC and found that it has got good clinical and pathological correlation. The results also show that 
strong stromal versican expression is an adverse prognostic sign in OSCC. Stromal Versican 
expression seems to be an independent prognostic marker in OSCC. 
STAT1:  
The signal transducer and activator of transcription1 (STAT1) has been implicated in triggering 
apoptosis and/or cell-cycle arrest (Battle, 2002). The signal transducer and activator of transcription 1 
(STAT1) has frequently been found to be constitutively activated in a great variety of tumors, including 
head and neck cancer.  In the study by Klausleimer et al. (2006) STAT1 activation was found only in 
18% of patient. In compared to STAT 1 expression in  head and neck cancers which had  statistically 
significant relation to prognosis, the study by Klausleimer et al. (2006), STAT1 expression was not 
associated with statistically significant survival rate probably because of very small numbers. 
Cyr61:  
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Cysteine-rich61 (Cyr61) is a member of the CCN (Cyr61/CTGF/Nov) protein family associated with 
angiogenesis, cell proliferation, adhesion, migration, and differentiation (Leask, 2006). Elevated 
expression of Cyr61 is associated with growth and progression of gastric cancer, breast cancer, ovarian 
cancer, and glioma. On the other hand, Cyr61 has also been shown to behave as a tumor suppressor in 
prostate cancer, uterine leiomyoma, nonsmall cell lung cancer, and endometrial cancer.  Kang et al., 
found that overexpression of Cyr61 is associated with the invasive phenotype of oral SCC cells in vitro. 
Sang-Hneg kok et al. (2009), Cyr61 has significant clinical correlation and is a independent prognostic 
marker for OSCC.  
MUC4:  
Mucins are membrane-bound or membrane-secreted glycoproteins expressed in epithelial cells 
(Holliningsworth, 2004). mucins are involved in the differentiation and renewal of the epithelium and 
modulation of cell adhesion, immune response, and cell signaling (Moniaux, 2001). MUC4 promotes 
tumor progression by repressing apoptosis multiplemechanisms, both ErbB2 dependent and 
independent. By knockdown and overexpression of MUC4 in cancer cells, the studies have 
demonstrated the anti-apoptotic function of MUC4.  Tomofumi Hamada et al. (2006), confirmed the 
results obtained in other carcinoma, by studying MUC4 in OSCC correlating significantly with tumor 
size, metastasis, and clinical staging factors which are associated with poor prognosis.  
A critical point that has to be reiterated is the fact that an ideal tumor marker has to show a high level 
of sensitivity and specificity. None of the tumor marker analyzed has all the characters for an ideal 
tumor marker, majority of them have very poor sensitivity and specificity.  
In summary, substantial discovery still awaits to be made in this field, and methodologies for the 
clinical evaluation of existing and novel biomarkers have yet to be explored. While much could be 
gained from the discovery of more novel biomarkers for early detection of OSCC, prediction of the 
malignant potential of the disease, and guidance of individualized therapy for patients, the near future 
of OSCC prognosis may eventually come to count on a few “elite club” biomarkers, which hopefully 
will accurately predict the incidence, stage, and progression of the disease, as well as reliably evaluate 
drug development.  
 
5. Conclusion 
An ideal biomarker has to show a high level of specificity and sensitivity to prevent false-positive 
screening tests, which will create anxiety in patients and lead to more expensive and invasive testing. 
Thus far, studies, although inconclusive, have found that the likelihood of identifying a biomarker with 
such sensitivity and specificity may be slim, at least for the immediate future. Therefore, combining 
markers is thought to be the next best thing to improve the accuracy of diagnosing, treating, and 
surveillance of recurrence of oral squamous cell carcinoma.  
 
6. Limitations   
The number of articles reviewed is minimal; Time limit search is done so the number of article 
contributed in this review is minimal, search is done only in   English literature. Major limitation of all 
the studies is that none of the study is a prospective study and studied only in one centre with limited 
number of samples so the real value of the tumor marker in assessing the prognosis can be arrived only 
by more prospective studies in various population groups. None of the novel tumor marker reviewed 
has any specific relation to OSCC and none of the tumor marker (except Septin) is expressed in more 
than 90% of patients, so none of them has diagnostic value also.  
 
7. Implications for practice  
None of the tumor marker reviewed has a immediate practical value in diagnosing or assessing the 
prognosis in OSCC without further confirmation. 
 
8. Implications for research  
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All these tumor markers can be studied prospectively and their value in predicting the tumor recurrence 
and prognosis can be assessed. More sophisticated techniques can further validate the potential use of 
these new markers. 
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Table 1: Description of Studies 
No 
Novel  Tumor 
Marker Study Topic Author 
No of 
cases 
Result 
Sig. + ve _ve 
1 TROP2 TROP2  a novel prognostic 
Marker in squamous cell 
Carcinoma of oral cavity 
Dominic  
Fong Et al  
90 52 38 0.140 
2  Periostin Periostin is frequently expressed 
and Enhances invasion and 
angiogenesis In oral cancer  
BSMS  
Siriwardena 
et al  
74 51 23 0.001 
3 SENP5 Overexpression of SENP5 in oral 
Squamous cell carcinoma and its 
Association with differentiation 
Xiaojun  
Ding et al 
48 36 12 0.001 
4 mGluR5  Clinical significance of metabo – 
Tropic glutamate receptor 5  
Expression in oral sq. cell CA 
So Yean Park 
et al 
131 94 37 0.000 
5 Septin1 Overexpression of Septin 1 : 
Possible contribution to the 
Development of oral cancer 
Yoshikuni 
kato 
et al  
85 77 8 0.000 
6 Stathmin Overexpression of stathmin in  
OSCC: correlation with tumor 
Progression and poor prognosis  
Y Kouzu 
Et al  
81 53 28 0.005 
7 IMP3 Insulin like growth factor II m 
RNA  
Binding protein 3 : a novel  
Prognostic biomarker for  OSCC 
Shengjin Li 
et al 
96 65 31 0.001 
8 Tapasin Downregulation of tapasin 
expression In primary huma 
OSCC : association  With 
clinical outcome  
Qian Jing 
et al 
67 38 29 0.272 
 
   
9 STAT1 STAT1 activation in Squamous 
Cell Carcinoma  of oral cavity 
Klaus laimer 
Et  al  
99 73 16 0.472 
10 Stromal  
Versican 
High stromal versican expression  
Predicts unfavorable outcome in 
OSCC 
Matti pukkila 
Et al 
139 75 64 0.02 
11 Cyr61 Expression in CYR61 in Human 
OSCC : An independent marker 
for Poor prognosis  
Sang  
Hengkok 
Et al 
93 74 19 0.01 
12 MUC4  MUC4 is a novel prognostic 
marker for  OSCC 
Tomofumi  
Hamada 
Et al  
150 61 89 0.771 
Sig. - Significant 
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Table 2: Tumor Markers and Their Clinical &  Histopathological Correlation and Prognosis 
No Marker 
No of 
Cases 
Expressio
n 
Clinica
l 
Staging 
I/II vs 
III/IV 
Pathological 
grading 
Clinicopathologica
l 
Correlation Prognosis 
1 TROP2 90 58% 0.41 0.46 No statistical 
correlation 
Over expression 
decrease overall 
survival p<0.01 
2 Periostin 74 69% 0.005      - Strong  
clinical 
correlation 
- 
3 SENP5 48 75% 0.520 0.01 Good 
histopathological 
correlation, no 
significant clinical 
correlation 
No statistical 
correlation 
between SENP5 
& oscc 
4 mGluR5 131 72% 0.0001 0.697 Significant 
clinical  
Correlation but no 
histopathological 
correlation 
Increase 
expression of 
mGLUR5 
decreases the 
overall survival 
5 Septin1 85 91% 0.155 0.016 Good 
histopathological 
correlation but no 
clinical 
correlation 
Not significant  
6 Stathmin 81 65% 0.035 0.999 Significant 
clinical 
correlation but no 
histopathological 
correlation 
Overall survival 
rate stathmin 
+ve&-ve is 
(p=0.16) 
7 IMP3  96 68% 0.038 0.005 Good clinical 
Correlation as 
well as 
histopathological 
correlation  
Positive 
expression 
decreases 
survival(p= 0.07) 
8 Tapasin 
(Down 
Regulation) 
67 57% >0.05 0.02 Downregulation 
of tapasin 
expression has a 
statistically 
significant 
correlation to poor 
differentiation and 
clinical staging 
Increased 
expression good 
prognosis and 
overall survival(p 
9 Stromal 
Versican 
139 46% 
( higher 
Versican 
Score 
index) 
< 
0.001 
0.005 Higher versican 
score index 
correlates well 
with tumor stage, 
size, metastasis 
and differentiation 
High stromal 
versican 
unfavourable 
prognosis p=0.048 
10 STAT1 89 18% NS 
 
NS It has very poor 
correlation to 
clinical 
Staging and 
pathological 
differentiation 
STAT1 activation 
& expression 
shows increased 
survival 
rate(p=0.03) 
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11 Cyr61 93 24% 0.036 0.720 Has good 
correlation to 
clinical staging 
but poor 
correlation to 
differentiation 
High expression 
poor 
survival(p=0.01) 
12 MUC4 150 40% 0.002 0.083 Has got good 
clinical 
correlation but 
poor pathological 
correlation 
survival rates of 
patients with 
MUC4 expression 
were significantly 
worse than those 
of MUC4-
negative patients 
(p=0.0001) 
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